<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patel, Aniruddh P</style></author><author><style face="normal" font="default" size="100%">Wang, Minxian</style></author><author><style face="normal" font="default" size="100%">Fahed, Akl C</style></author><author><style face="normal" font="default" size="100%">Mason-Suares, Heather</style></author><author><style face="normal" font="default" size="100%">Brockman, Deanna</style></author><author><style face="normal" font="default" size="100%">Pelletier, Renee</style></author><author><style face="normal" font="default" size="100%">Amr, Sami</style></author><author><style face="normal" font="default" size="100%">Machini, Kalotina</style></author><author><style face="normal" font="default" size="100%">Hawley, Megan</style></author><author><style face="normal" font="default" size="100%">Witkowski, Leora</style></author><author><style face="normal" font="default" size="100%">Koch, Christopher</style></author><author><style face="normal" font="default" size="100%">Philippakis, Anthony</style></author><author><style face="normal" font="default" size="100%">Cassa, Christopher A</style></author><author><style face="normal" font="default" size="100%">Ellinor, Patrick T</style></author><author><style face="normal" font="default" size="100%">Kathiresan, Sekar</style></author><author><style face="normal" font="default" size="100%">Ng, Kenney</style></author><author><style face="normal" font="default" size="100%">Lebo, Matthew</style></author><author><style face="normal" font="default" size="100%">Khera, Amit V</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History.</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Netw Open</style></secondary-title><alt-title><style face="normal" font="default" size="100%">JAMA Netw Open</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Colorectal Neoplasms, Hereditary Nonpolyposis</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Hereditary Breast and Ovarian Cancer Syndrome</style></keyword><keyword><style  face="normal" font="default" size="100%">Heterozygote</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Hyperlipoproteinemia Type II</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Pedigree</style></keyword><keyword><style  face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style  face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style  face="normal" font="default" size="100%">Whole Exome Sequencing</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 04 01</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">3</style></volume><pages><style face="normal" font="default" size="100%">e203959</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;Importance: &lt;/b&gt;Pathogenic DNA variants associated with familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and Lynch syndrome are widely recognized as clinically important and actionable when identified, leading some clinicians to recommend population-wide genomic screening.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Objectives: &lt;/b&gt;To assess the prevalence and clinical importance of pathogenic or likely pathogenic variants associated with each of 3 genomic conditions (familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and Lynch syndrome) within the context of contemporary clinical care.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Design, Setting, and Participants: &lt;/b&gt;This cohort study used gene-sequencing data from 49 738 participants in the UK Biobank who were recruited from 22 sites across the UK between March 21, 2006, and October 1, 2010. Inpatient hospital data date back to 1977; cancer registry data, to 1957; and death registry data, to 2006. Statistical analysis was performed from July 22, 2019, to November 15, 2019.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Exposures: &lt;/b&gt;Pathogenic or likely pathogenic DNA variants classified by a clinical laboratory geneticist.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Main Outcomes and Measures: &lt;/b&gt;Composite end point specific to each genomic condition based on atherosclerotic cardiovascular disease events for familial hypercholesterolemia, breast or ovarian cancer for hereditary breast and ovarian cancer syndrome, and colorectal or uterine cancer for Lynch syndrome.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results: &lt;/b&gt;Among 49 738 participants (mean [SD] age, 57 [8] years; 27 144 female [55%]), 441 (0.9%) harbored a pathogenic or likely pathogenic variant associated with any of 3 genomic conditions, including 131 (0.3%) for familial hypercholesterolemia, 235 (0.5%) for hereditary breast and ovarian cancer syndrome, and 76 (0.2%) for Lynch syndrome. Presence of these variants was associated with increased risk of disease: for familial hypercholesterolemia, 28 of 131 carriers (21.4%) vs 4663 of 49 607 noncarriers (9.4%) developed atherosclerotic cardiovascular disease; for hereditary breast and ovarian cancer syndrome, 32 of 116 female carriers (27.6%) vs 2080 of 27 028 female noncarriers (7.7%) developed associated cancers; and for Lynch syndrome, 17 of 76 carriers (22.4%) vs 929 of 49 662 noncarriers (1.9%) developed colorectal or uterine cancer. The predicted probability of disease at age 75 years despite contemporary clinical care was 45.3% for carriers of familial hypercholesterolemia, 41.1% for hereditary breast and ovarian cancer syndrome, and 38.3% for Lynch syndrome. Across the 3 conditions, 39.7% (175 of 441) of the carriers reported a family history of disease vs 23.2% (34 517 of 148 772) of noncarriers.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions and Relevance: &lt;/b&gt;The findings suggest that approximately 1% of the middle-aged adult population in the UK Biobank harbored a pathogenic variant associated with any of 3 genomic conditions. These variants were associated with an increased risk of disease despite contemporary clinical care and were not reliably detected by family history.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32347951?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turner, Tychele N</style></author><author><style face="normal" font="default" size="100%">Hormozdiari, Fereydoun</style></author><author><style face="normal" font="default" size="100%">Duyzend, Michael H</style></author><author><style face="normal" font="default" size="100%">McClymont, Sarah A</style></author><author><style face="normal" font="default" size="100%">Hook, Paul W</style></author><author><style face="normal" font="default" size="100%">Iossifov, Ivan</style></author><author><style face="normal" font="default" size="100%">Raja, Archana</style></author><author><style face="normal" font="default" size="100%">Baker, Carl</style></author><author><style face="normal" font="default" size="100%">Hoekzema, Kendra</style></author><author><style face="normal" font="default" size="100%">Stessman, Holly A</style></author><author><style face="normal" font="default" size="100%">Zody, Michael C</style></author><author><style face="normal" font="default" size="100%">Nelson, Bradley J</style></author><author><style face="normal" font="default" size="100%">Huddleston, John</style></author><author><style face="normal" font="default" size="100%">Sandstrom, Richard</style></author><author><style face="normal" font="default" size="100%">Smith, Joshua D</style></author><author><style face="normal" font="default" size="100%">Hanna, David</style></author><author><style face="normal" font="default" size="100%">Swanson, James M</style></author><author><style face="normal" font="default" size="100%">Faustman, Elaine M</style></author><author><style face="normal" font="default" size="100%">Bamshad, Michael J</style></author><author><style face="normal" font="default" size="100%">Stamatoyannopoulos, John</style></author><author><style face="normal" font="default" size="100%">Nickerson, Deborah A</style></author><author><style face="normal" font="default" size="100%">McCallion, Andrew S</style></author><author><style face="normal" font="default" size="100%">Darnell, Robert</style></author><author><style face="normal" font="default" size="100%">Eichler, Evan E</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Genome Sequencing of Autism-Affected Families Reveals Disruption of Putative Noncoding Regulatory DNA.</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Hum Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Am J Hum Genet</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Autistic Disorder</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Exome</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome, Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Pedigree</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Jan 07</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">98</style></volume><pages><style face="normal" font="default" size="100%">58-74</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We performed whole-genome sequencing (WGS) of 208 genomes from 53 families affected by simplex autism. For the majority of these families, no copy-number variant (CNV) or candidate de novo gene-disruptive single-nucleotide variant (SNV) had been detected by microarray or whole-exome sequencing (WES). We integrated multiple CNV and SNV analyses and extensive experimental validation to identify additional candidate mutations in eight families. We report that compared to control individuals, probands showed a significant (p = 0.03) enrichment of de novo and private disruptive mutations within fetal CNS DNase I hypersensitive sites (i.e., putative regulatory regions). This effect was only observed within 50 kb of genes that have been previously associated with autism risk, including genes where dosage sensitivity has already been established by recurrent disruptive de novo protein-coding mutations (ARID1B, SCN2A, NR3C2, PRKCA, and DSCAM). In addition, we provide evidence of gene-disruptive CNVs (in DISC1, WNT7A, RBFOX1, and MBD5), as well as smaller de novo CNVs and exon-specific SNVs missed by exome sequencing in neurodevelopmental genes (e.g., CANX, SAE1, and PIK3CA). Our results suggest that the detection of smaller, often multiple CNVs affecting putative regulatory elements might help explain additional risk of simplex autism.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26749308?dopt=Abstract</style></custom1></record></records></xml>